Clinical Trial Update: A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin [Phase 3]

View source ↗

Summary

A Phase 3 sub-study evaluating 24 weeks of initial combination therapy with vildagliptin plus metformin in adults with Type 2 diabetes mellitus; study completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Vildagliptin (vildagliptin)
• metformin (metformin)

Snippet

Sponsor: Novartis | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED